Parkinson's disease: current and future challenges

J William Langston1

  • 1The Parkinson's Institute, Sunnyvale, CA 94089, USA. jwlangston@parkinsonsinstitute.org

Neurotoxicology
|November 14, 2002
PubMed

Insights

Unraveling the etiology of Parkinson's disease (PD) by its 200th anniversary requires focused research. This review examines the genes versus environment debate and clarifies disease definitions to guide future PD research.

Area of Science:

  • Neuroscience
  • Genetics
  • Environmental Health

Background:

  • Parkinson's disease (PD) was first described in 1817.
  • Understanding PD's cause is a major scientific challenge.
  • The 200th anniversary of PD's description is approaching.

Purpose of the Study:

  • To review the "genes versus environment" debate in PD etiology.
  • To address controversies in PD definition and terminology.
  • To identify key research areas for unraveling PD's cause.

Main Methods:

  • Literature review of the "genes versus environment" debate.
  • Analysis of issues surrounding PD definition and terminology.
  • Synthesis of future research directions for PD.

Main Results:

  • The relative roles of genes and environment in PD causation remain controversial.
  • Controversy extends to the definition and disease status of PD.
  • Clarity on these issues is crucial for efficient research.

Conclusions:

  • Resolving the "genes versus environment" debate is essential for understanding PD.
  • Standardized definitions are needed for coherent research.
  • Strategic research focus is required to determine PD etiology.

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...